1. Home
  2. PDM vs CMPX Comparison

PDM vs CMPX Comparison

Compare PDM & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Piedmont Office Realty Trust Inc.

PDM

Piedmont Office Realty Trust Inc.

HOLD

Current Price

$8.23

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDM
CMPX
Founded
1997
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
927.5M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
PDM
CMPX
Price
$8.23
$1.98
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$9.00
$14.57
AVG Volume (30 Days)
1.2M
10.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$564,994,000.00
N/A
Revenue This Year
$4.21
N/A
Revenue Next Year
$1.29
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.32
$1.61
52 Week High
$9.19
$6.88

Technical Indicators

Market Signals
Indicator
PDM
CMPX
Relative Strength Index (RSI) 68.47 24.81
Support Level $8.03 $1.61
Resistance Level $8.89 $3.74
Average True Range (ATR) 0.25 0.47
MACD 0.05 -0.37
Stochastic Oscillator 81.51 6.97

Price Performance

Historical Comparison
PDM
CMPX

About PDM Piedmont Office Realty Trust Inc.

Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: